Roheena Z Panni1, Alexandra G Lopez-Aguiar2, Jingxia Liu3, George A Poultsides4, Flavio G Rocha5, William G Hawkins1, Steven M Strasberg1, Nikolaos A Trikalinos6, Shishir Maithel2, Ryan C Fields1. 1. Division of HPB and GI Surgery, Washington University School of Medicine, St. Louis, Missouri. 2. Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia. 3. Section of Oncologic Biostatistics, Division of Public Health, Washington University School of Medicine, St. Louis, Missouri. 4. Department of Surgery, Stanford University Medical Center, Stanford, California. 5. Department of Surgery, Virginia Mason Medical Center, Seattle, Washington. 6. Department of Medicine, Washington University in St. Louis, St. Louis, Missouri.
Abstract
BACKGROUND: Preoperative systemic inflammatory response plays a crucial role in tumorigenesis, progression, and prognosis; and neutrophil, monocyte, and lymphocyte counts serve as important biomarkers. An altered monocyte-to-lymphocyte ratio (MLR) and neutrophil-to-lymphocyte ratio (NLR) has been reported to be associated with a favorable prognosis for certain hematologic malignancies and breast cancer. The aim of this study was to investigate the prognostic significance of MLR, NLR in patients with resectable PNETs. METHODS: Patients undergoing surgery for PNETs between 2000 and 2016 were identified using a large, multi-center database. NLR and MLR were calculated and Contal and O'Quigley analysis was used to determine the optimal cutoff value. RESULTS: A total of 620 patients were included in the analytic cohort. The prognostic implications of blood count parameters were evaluated in both univariate and multivariate analysis. The univariate analysis revealed that low MLR and NLR is associated with significantly improved overall survival (OS; P < .01) and recurrence-free survival (RFS; P < .01). On multivariate analysis, in addition to tumor size and grade, NLR was an independent predictor of improved OS and RFS. CONCLUSION: In addition to established tumor-specific factors, preoperative NLR levels can serve as a valuable biomarker that can be used as a predictor of OS and RFS after resection of PNETs.
BACKGROUND: Preoperative systemic inflammatory response plays a crucial role in tumorigenesis, progression, and prognosis; and neutrophil, monocyte, and lymphocyte counts serve as important biomarkers. An altered monocyte-to-lymphocyte ratio (MLR) and neutrophil-to-lymphocyte ratio (NLR) has been reported to be associated with a favorable prognosis for certain hematologic malignancies and breast cancer. The aim of this study was to investigate the prognostic significance of MLR, NLR in patients with resectable PNETs. METHODS:Patients undergoing surgery for PNETs between 2000 and 2016 were identified using a large, multi-center database. NLR and MLR were calculated and Contal and O'Quigley analysis was used to determine the optimal cutoff value. RESULTS: A total of 620 patients were included in the analytic cohort. The prognostic implications of blood count parameters were evaluated in both univariate and multivariate analysis. The univariate analysis revealed that low MLR and NLR is associated with significantly improved overall survival (OS; P < .01) and recurrence-free survival (RFS; P < .01). On multivariate analysis, in addition to tumor size and grade, NLR was an independent predictor of improved OS and RFS. CONCLUSION: In addition to established tumor-specific factors, preoperative NLR levels can serve as a valuable biomarker that can be used as a predictor of OS and RFS after resection of PNETs.
Authors: Patrick B Schwartz; George Poultsides; Kevin Roggin; John H Howard; Ryan C Fields; Callisia N Clarke; Konstantinos Votanopoulos; Kenneth Cardona; Emily R Winslow Journal: J Surg Res Date: 2020-03-12 Impact factor: 2.192
Authors: Fiona Ohlendorf; Rudolf A Werner; Christoph Henkenberens; Tobias L Ross; Hans Christiansen; Frank M Bengel; Thorsten Derlin Journal: Diagnostics (Basel) Date: 2021-03-12
Authors: Pedro Marques; Friso de Vries; Olaf M Dekkers; Márta Korbonits; Nienke R Biermasz; Alberto M Pereira Journal: J Clin Endocrinol Metab Date: 2021-09-27 Impact factor: 5.958